IRIS
TESTA, ROBERTO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 9.920
AS - Asia 30
SA - Sud America 6
NA - Nord America 1
Totale 9.957
Salva come PNG Salva come JPEG
Nazione #
IT - Italia 9.919
CN - Cina 23
BR - Brasile 6
VN - Vietnam 6
HK - Hong Kong 1
MX - Messico 1
RU - Federazione Russa 1
Totale 9.957
Salva come PNG Salva come JPEG
Città #
Genova 6.578
Genoa 1.866
Rapallo 870
Vado Ligure 589
Bordighera 16
Beijing 14
Ho Chi Minh City 2
Apodaca 1
Bagé 1
Bắc Giang 1
Cachoeiro de Itapemirim 1
Can Tho 1
Cà Mau 1
Duque de Caxias 1
Goiana 1
Hanoi 1
Hong Kong 1
Inhambupe 1
Uberlândia 1
Yaroslavl 1
Totale 9.948
Salva come PNG Salva come JPEG
Nome #
5-ASA and colorectal cancer chemoprevention in inflammatory bowel disease: can we afford to wait for “best evidence”? 190
13C -Aminopyrine breath test to evaluate severity of disease in patients with chronic hepatitis C virus infection. 183
Leptin has no role in determining severity of steatosis and fibrosis in patients with chronic hepatitis C 181
13C-galactose breath test and 13C-aminopyrine breath test for the study of liver function in chronic liver disease 173
A simple approach to noninvasively identifying significant fibrosis in chronic hepatitis C patients in clinical practice 166
A study of 4-and 7-day triple therapy with rabeprazole, high-dose levofloxacin and tinidazole rescue treatment for Helicobacter pylori eradication 165
Splanchnic haemodynamic effects of ketanserin in anaesthetized cirrhotic rats. 162
Application of the platelet count/spleen diameter ratio to rule out the presence of oesophageal varices in patients with cirrhosis: a validation study based on follow-up 160
Cholestasis is the main determinant of abnormal CA 19-9 levels in patients with liver cirrhosis 155
. Liver iron accumulation in chronic hepatittis C patients without HFE mutations: relationships with histological damage, viral load and genotype, and alpha glutathione S-transferase levels. 150
Hyaluronic acid and aspartate aminotransferase levels normalized by liver function can reflect sinusoidal impairment in chronic liver disease 149
Utility of the MELD score for assessing 3-month survival in patients with liver cirrhosis: one more positive answer. 146
Can the MEGX test and serum bile acids improve the prognostic ability of Child-Pugh's score in liver cirrhosis? 146
Effects of reduced glutathione and n-acetylcysteine on lidocaine metabolism in cimetidine treated rats 144
Prevalence and prognostic significance of the presence of esophageal varices in patients with hepatocellular carcinoma 143
Is there a role for multiple quantitative liver function tests? 140
Transportability and reproducibility of the AST/ALT ratio in chronic hepatitis C patients. 140
Comparison between laparoscopy, ultrasonography, and computed tomography in widespread and localized liver diseases. 140
Leptin in nonalcoholic steatohepatitis: is it one of the "hits"? 140
Chronic hepatitis C in different populations: similar patterns of alanine aminotransferase alteration characterize similar clinical subgroups. 136
MELD scoring system is useful for predicting prognosis in patients with liver cirrhosis and is correlated with residual liver function: a European study 136
Serum pro-collagen III peptide levels are related to lobular necrosis in untreated patients with chronic hepatitis C 136
Influence of Helicobacter pylori eradication therapy on 13C aminopyrine breath test: comparison among omeprazole-, lansoprazole-, or pantoprazole-containing regimens 135
High ascitic fluid leptin levels in patients with decompensated liver cirrhosis and sterile ascites: Relationship with TNF-alpha levels 131
Persistently normal aminotransferase in chronic hepatitis C virus infection: is it time to redefine parameters of "normality"? 128
Reply to Farinati et al.: classification of 'intermediate stage', untreated hepatocellular carcinoma patients: the neighbour's grass is not so green 127
Tryglycylvasopressin-reduced portal and systemic concentrations of serum bile acids after exogenous chenodeoxycholic acid load in rats as a reflection of reduced splanchnic blood flow 127
The monoethylglycinexylidide test does not impair psychometric performance in patients with chronic hepatitis or cirrhosis 126
Propranolol reduces the response of serum bile acids to oral chenodeoxycholic acid, possibly as a reflex reaction to reduced portal blood flow in healthy and cirrhotic subjects. 126
Liver enzyme alteration: a guide for clinicians 126
Is aspartate aminotransferase enough? 125
13CO2 excretion in breath of normal subjects and cirrhotic patients after 13C-Aminopyrine oral load. Comparison with MEGX test in functional differentiation between chronic hepatitis and liver cirrhosis 124
Steatosis in chronic hepatitis C: can weight reduction improve therapeutic efficacy? 124
Trans-catheter arterial chemoembolisation for hepatocellular carcinoma in patients with viral cirrhosis: role of combined staging systems, Cancer Liver Italian Program (CLIP) and Model for End-stage Liver Disease (MELD), in predicting outcome after treatment 122
Influence of 1-week helicobacter pylori eradication therapy with rabeprazole, clarithromycin, and metronidazole on 13C-aminopyrine breath test 122
HOMA, BMI, and serum leptin levels variations during antiviral treatment suggest virus-related insulin resistance in noncirrhotic, nonobese, and nondiabetic chronic hepatitis C genotype 1 patients 121
Can changing counseling strategy change the picture of the chronic hepatitis C patient population? 119
Steatosis and bile duct damage in chronic hepatitis C: distribution and relationships in a group of Northern Italian patients 119
Two or more synchronous combination of noninvasive test to increase accuracy of liver fibrosis in chronic hepatitis C. 118
Serum leptin levels in patients with viral chronic hepatitis or liver cirrhosis 118
The 1-year and 3-month prognostic utility of the AST/ALT ratio and model for end-stage liver disease score in patients with viral liver cirrhosis 116
Influence of age on clinical presentation, therapeutic options, and prognosis in anti-HCV positive cirrhotic patients with hepatocellular carcinoma 116
Platelet count/spleen diameter ratio for the noninvasive diagnosis of esophageal varices: results of a multicenter, prospective, validation study 113
Previous hepatitis B virus infection is associated with worse disease stage and occult hepatitis B virus infection has low prevalence and pathogenicity in hepatitis C virus-positive patients 112
Surveillance for hepatocellular carcinoma in liver cirrhosis: have programmes improved because patients have? 112
Impairment of cytochrome P-450-dependent liver activity in cirrhotic patients with Helicobacter pylori infection. 111
Caffeine clearance in subjects with constitutional un conjugated hyperbilirubinemia 110
Eligibility criteria for antiviral therapy in HCV-positive patients: similar things to (almost) similar people 109
Leptin levels in nonalcoholic steatohepatitis and chronic hepatitis C 109
Does surveillance for hepatocellular carcinoma in HCV cirrhotic patients improve treatment outcome mainly due to better clinical status at diagnosis? 107
Progressive liver functional impairment is associated with an increase in AST/ALT ratio 106
Longitudinal modifications of the MELD score have prognostic meaning in patients with liver cirrhosis 106
Analysis of circadian fluctuations of bile salt concentration and pH in the stomach of normal subjects and patients suspected of having duodenogastric reflux. 106
Effects of Interferon therapy on monoethylglycinexylidide formation in patients with chronic active hepatitis C 105
Serum thrombopoietin levels are linked to liver function in untreated patients with hepatitis C virus-related chronic hepatitis 103
Formation kinetics of the lidocaine metabolite (MEGX) in patients with chronic active hepatitis and cirrhosis 101
Relationship between thrombopoietin serum levels and liver function in patients with chronic liver disease related to hepatitis C virus infection 99
Chronic liver disease related to hepatitis C virus: age of patients seems to be a determinant of severity independently of viral genotype 98
Monoethylglycinexylidide formation measurement as a hepatic function test to assess severity of chronic liver disease. 98
Histological determinants of monoethylglycinexylidide formation in patients with chronic hepatitis C 98
Prediction of oesophageal varices with platelet count/spleen diameter ratio or platelets alone. 97
Increased levels of gammaGT suggest the presence of bile duct lesions in patients with chronic hepatitis C: absence of influence of HCV genotype, HCV-RNA serum levels, and HGV infection on this histological damage 94
The metabolic syndrome: all criteria are equal, but some criteria are more equal than others. 91
Proposal and Validation of the AST/ALT ratio for predicting the presence of significant fibrosis in patients with chronic hepatitis C. 90
Non-invasive assessment of liver function: trying not to miss an opportunity. 90
Effects of the association of lansoprazole, clarithromycin and metronidazole for Helicobacter Pylori eradication therapy, measured by the 13C Aminopyrine breath test. 89
Validity and clinical utility of the aspartate aminotransferase-alanine aminotransferase ratio in assessing disease severity and prognosis in patients with hepatitis C virus-related chronic liver disease 89
Wilson's disease with concomitant beta thalassaemia and factor V deficiency. 88
Biochemical scores could reflect histological activity in chronic hepatitis C 88
Monitoring of liver metabolic function during interferon-alpha therapy and its relationship to treatment outcome in chronic hepatitis C patients 86
Monitoring cytochrome P-450 activity during rabeprazole treatment in patients with gastroesophageal reflux disease. 86
Omeprazole decreased formation of monoethylglycinexylidide in a patient with chronic active hepatitis. 83
Serum prolyl-hydroxylase as an index of fibrogenic activity in chronic active hepatitis and cirrhosis 83
Oral or intravenous lidocaine administration to perform megx test? 83
Therapeutic management of chronic hepatitis B in clinical Practice: a region-wide survey. 82
Probability of non-response during interferon therapy in patients with chronic hepatitis C 81
Lidocaine elimination and monoethylglycinexylidide formation in patients with chronic hepatitis or cirrhosis. 80
Inclusion of serum bile acids in Child-Turcotte-Pugh's score can improve grading assessment of alcoholic cirrhosis. 79
13C-breath tests and liver fibrosis. 76
Postprandial serum bile acids after ursodeoxycholic acid. A possible test of intestinal absorption? 76
The Italian Registry of Therapeutic Apheresis: granulocyte-monocyte apheresis in the treatment of inflammatory bowel disease. A multicentric study. 75
Plasma aminoacid ratios in alcoholic cirrhotics with subclinical encephalopathy: relationships with cerebral blood flow. 74
Tauroursodeoxycholic acid administration as adjuvant therapy in cirrhotic patients on transplantation waiting lists. 73
Malattie epatiche congenite 65
Serum bile acid profiles after endogenous and exogenous loads of bile acid into the enterohepatic circulation of healthy subjects and patiens with chronic liver disease. 63
Long-term follow-up of chronic hepatitis C patients after interferon alpha treatment: a clinical and functional study 61
Helicobacter pylori infection is associated with greater impairment of cytochrome P-450 liver metabolic activity in anti-HCV positive cirrhotic patients. 49
Predictors of clinical response in patients with ulcerative colitis treated with granulocyte-monocyte apheresis: analysis of the apheresis registry data 43
Totale 9.968
Salva come PNG Salva come JPEG
Categoria #
all - tutte 32.373
article - articoli 31.648
book - libri 0
conference - conferenze 272
curatela - curatele 0
other - altro 230
patent - brevetti 0
selected - selezionate 0
volume - volumi 223
Totale 64.746
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021343 0 0 0 31 30 55 14 32 57 44 38 42
2021/20221.087 17 134 89 94 24 39 77 304 29 91 58 131
2022/20231.042 101 62 7 84 195 176 1 83 140 2 181 10
2023/2024408 18 68 8 57 35 48 13 29 14 5 43 70
2024/20251.349 50 112 39 76 195 150 100 245 51 52 111 168
2025/2026579 281 30 113 155 0 0 0 0 0 0 0 0
Totale 9.968